Eur Rev Med Pharmacol Sci 2022; 26 (21): 7996-8003

DOI: 10.26355/eurrev_202211_30153

Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity

X.-Y. Li, C.-P. Li, C.-Y. Zhang, S. Zhang, J.-X. Chen, D. Zhu, F.-W. Chen, Z.-Z. Wu, D.-C. Hou, C.-Y. Zheng, K.-J. Hou

Graduate School, Guangzhou University of Chinese Medicine, Guangzhou City, Guangdong Province, China. kaijianhou@126.com


OBJECTIVE: To explore the effect of polyethylene glycol loxenatide (long-acting GLP-1R agonist) on the lipid, glucose levels, and weight in type 2 diabetes mellitus patients with obesity.

PATIENTS AND METHODS: A total of 40 obese patients with type 2 diabetes mellitus in our hospital from July 2019 to June 2020 were randomly divided into a control group and a study group. The study group was treated with metformin and polyethylene glycol loxenatide injection, while the control group was treated with metformin.

RESULTS: Before treatment, there was no significant difference in FPG (Fasting Blood Glucose) and PPG (Post Prandial Glycaemia) levels between the study group and the control group (p>0.05). After a treatment period, the FPG and PPG levels in the study group were significantly lower than those in the control group (p<0.05). With the longer treatment time, the patient’s weight and BMI were lower (p<0.05). The weight and BMI of patients changed the least after one month of treatment, and the weight and BMI changed the most after more than seven months of treatment. After a period of treatment, the levels of FPG and PPG in the blood of male patients in the study group were significantly lower than those of female patients (p<0.05). After treatment, the TG level of the study group was significantly lower than that of the control group (p<0.05). In comparison, the HDL-C level was significantly higher than that of the control group (p<0.05).

CONCLUSIONS: Lipid and glucose levels of type 2 diabetes mellitus patients with obesity have decreased after 12 weeks of polyethylene glycol loxanatide use. The weight of type 2 diabetes mellitus patients with obesity has changed after using polyethylene glycol loxenatide for a period of treatment. Among them, there is a certain relationship between body weight and treatment time, gender, and original body weight, which is worthy of further research and promotion in clinical practice.

Free PDF Download

To cite this article

X.-Y. Li, C.-P. Li, C.-Y. Zhang, S. Zhang, J.-X. Chen, D. Zhu, F.-W. Chen, Z.-Z. Wu, D.-C. Hou, C.-Y. Zheng, K.-J. Hou
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 21
Pages: 7996-8003
DOI: 10.26355/eurrev_202211_30153